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Human rhinoviruses and enteroviruses (family Picornaviridae) infect millions of
people worldwide each year, but little is known about effective therapeutical
treatment for the infection caused by these viruses. We sought to determine
whether or not Zanthoxylum (Rutaceae) species can exhibit antiviral activity
against picornaviruses. The leaf parts of four Zanthoxylum species were
extracted with methanol, and the extracts were investigated for their antiviral
activity against picornaviruses using cytopathic effects by cytopathic effect
reduction. Leaf extracts of Zanthoxylum piperitum among four Zanthoxylum
species were found to possess only broad-spectrum antipicornavirus activity
against human rhninovirus 2 with a 50% inhibitory concentration (IC50) value of
59.48 mg/mL, human rhinovirus 3 with an IC50 value of 39.94 mg/mL, coxsackie
A16 virus with an IC50 value of 45.80 mg/mL, coxsackie B3 virus with an IC50 value
of 68.53 mg/mL, coxsackie B4 virus with an IC50 value of 93.58 mg/mL, and
enterovirus 71 virus with an IC50 value of 4.48 mg/mL. However, ribavirin did not
possess antiviral activity against human rhinovirus 3 and four enteroviruses.
Therefore, leaves of Z. piperitum showed broad-spectrum antipicornavirus ac-
tivity, and may be useful as a candidate for studying picornavirus agents and
development of pharmaceuticals.1. Introduction
Human rhinoviruses (HRVs) belong, together with
enteroviruses, to the family Picornaviridae, and cause a
wide variety of diseases in humans and animals [1].
Infections with HRVs lead to the common cold with
symptoms such as sore throat, rhinitis, nasal congestion,
and cough [2]. HRVs also lead to severe respiratory tract
illnesses in children, immunosuppressed patients, and
the elderly [3,4]. Most enterovirus infections are
asymptomatic or result in only mild illness, but entero-
viruses can also cause a wide variety of clinical ill-
nesses, including acute hemorrhagic conjunctivitis,ase Control and Prevention.
reativecommons.org/licensaseptic meningitis, undifferentiated rash, acute flaccid
paralysis, myocarditis, and neonatal sepsis-like disease
[5]. Curing virus infections harbors an enormous eco-
nomic potential, and the search for new antiviral sub-
stances is of great interest for worldwide health. Despite
significant efforts, no antiviral agent is approved for the
prevention or treatment of HRV or enterovirus infection.
Zanthoxylum (Rutaceae) species has been used for
centuries as a source of spices in Asian cuisine and tradi-
tional Asian medicine [6e8]. In a previous study, leaf
extracts of Zanthoxylum piperitum were shown to possess
antiviral activities against influenzaA/WS/33,A/PR/8, and
B/Lee/40 viruses [9]. In this study,we aimed to identify thePublished by Elsevier Korea LLC. This is an open access article
es/by-nc-nd/4.0/).
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HRVs (HRV2andHRV3) or four enteroviruses (coxsackie
A16, B3, and B4 viruses, and human enterovirus 71).2. Materials and methods
Leaf parts from two Zanthoxylum species (Z. piperitum
and Zanthoxylum schinifolium) were collected from Mt.
Gwanggyo (Suwon, Korea), and another two Zanthox-
ylum species (Zanthoxylum coreanum and Zanthoxylum
planispinum) were collected from National Institute of
Forest Science, Seoul. Voucher specimens have been
identified by Soon-Il Lee (School of Agricultural
Biotechnology, Seoul National University, Seoul) and
deposited in the herbarium of the School of Agricultural
Biotechnology, Seoul National University [Z. piperitum
(ZP) leaves: ZP3; Z. schinifolium (ZS) leaves: ZS2; Z.
coreanum (ZC) leaves: ZC1; Z. planispinum (ZPS) ZP
leaves: ZP4]. Theywere air dried at room temperature and
pulverized. Each 100-g sample of the specimen plantswas
extracted twice with 600 mL of methanol at room tem-
perature for 3 days and filtered (Whatman No. 2). The
combined filtrate was concentrated to dryness by rotary
evaporation at 40C. Each extract was solubilized in
dimethyl sulfoxide at a concentration of 100 mg/mL and
stored at 20C.
HRV2 and HRV3 were provided by American Type
Culture Collection (Manassas, VA, USA) and were
propagated in human epitheloid carcinoma cervix (HeLa)
cells at 32C. Coxsackie A16, coxsackie B3, and cox-
sackie B4 viruses, and human enterovirus 71 (EV71) were
obtained from Chungcheongnam-Do Health and Envi-
ronment Research Institute in Korea, and were propagated
in African green monkey kidney (Vero) cells at 37C.
HeLa or Vero cells were maintained in minimal essential
medium supplemented with 10% fetal bovine serum and
0.01% antibioticeantimycotic. Antibioticeantimycotic,
trypsineEDTA, fetal bovine serum, andminimal essential
medium were supplied by Gibco BRL (Grand Island, NY,
USA). The tissue culture plates were purchased from
Falcon (BD Biosciences, Franklin Lakes, NJ, USA).
Ribavirin and sulforhodamine B (SRB) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Oseltamivir
(F. Hofmann-La Roche Ltd, Basel, Switzerland) was
purchased from a pharmacy in Korea as prescribed by a
medical doctor. All other chemicals were of reagent grade.
Assays of antiviral activity and cytotoxicity were
evaluated by the SRB method using cytopathic effect
reduction, already reported [10]. Briefly, 1 day prior to
infection, Vero or HeLa cells were seeded onto a 96-
well culture plate at a concentration of 2 104 cells/
well. The following day, the culture medium was
removed and cells were washed with phosphate-
buffered saline. The infectivity of each virus was
determined by the SRB method monitoring the cyto-
pathic effect, allowing for the percentage of cellviability to be determined. Based on the mammalian cell
viability determined for each virus, 0.09 mL of diluted
virus suspension containing 50% cell culture infective
dose of virus stock was added to mammalian cells. This
dose was selected to produce the appropriate cytopathic
effects 48 hours after infection. For compound treat-
ments, 0.01 mL of the medium containing the selected
concentration of the compound was added to the cells.
The antiviral activity of each test material was deter-
mined using a 10-fold diluted concentration range of
0.1e100 mg/mL. Four wells were used as virus controls
(virus-infected, nondrug-treated cells), and four wells
were used as cell controls (noninfected, nondrug-treated
cells). Culture plates were incubated at 37C in 5% CO2
for 48 hours. After washing once with phosphate-
buffered saline, 100 mL of cold (20C) 70% (v/v)
acetone was added to each well and left for 30 minutes
at 20C. The acetone was removed from cells, after
which 96-well plates were left to dry in an oven at 60C
for 30 minutes. Then, 100 mL of 0.4% (w/v) SRB in 1%
acetic acid (v/v) was added to each well and incubated at
room temperature for 30 minutes. Unbound SRB was
removed by washing the plates five times with 1% acetic
acid (v/v), and the plates were then left to dry in an
oven. After drying for 1 day, fixed SRB in wells was
solubilized with 100 mL of unbuffered Tris-base solu-
tion (10mM), and plates were incubated at room tem-
perature for 30 minutes. Absorbance in each well was
read at 540 nm using a VERSAmax microplate reader
(Molecular Devices, Palo Alto, CA, USA) and a refer-
ence absorbance of 620 nm. Ribavirin was used as a
positive and dimethyl sulfoxide as a negative control. To
calculate the 50% inhibitory concentration (IC50) values,
the results were transformed to percentage of controls
and the IC50 values were graphically obtained from the
doseeresponse curves. The percent protection achieved
by the test compound in virus-infected cells was
calculated by the following formula:
½ðODtÞvirus  ðODcÞvirus=½ðODcÞmock
 ðODcÞvirus  100ðexpressedin%Þ
where (ODt)virus is the optical density measured with a
given concentration of the test compound in virus-
infected cells, (ODc)virus is the optical density
measured for the control untreated virus infected cells,
and (ODc)mock is the optical density measured for the
control untreated mock-infected cells. The concentration
achieving 50% protection according to the above for-
mula was defined as the IC50. The therapeutic index was
defined as CC50/IC50.3. Results
Leaf parts of four Zanthoxylum species were inves-
tigated for its antiviral activity against picornaviruses
402 H.-J. Choi(HRV2, HRV3, coxsackie A16, coxsackie B3, coxsackie
B4, and EV71). Z. schinifolium and Z. planispinum,
from the tested crude extracts, were active against
HRV2. Their IC50 values were 47.05 mg/mL and
66.55 mg/mL, respectively, and their therapeutic index
values were 4e5. In addition, Z. planispinum showed
strong antiviral activity against HRV3, with an IC50
value of 29.58 mg/mL. Z. piperitum showed moderate
anti-HRV2 and anti-HRV3 activities. Z. piperitum
showed broad anti-coxsackie A16, anti-coxsackie B3,
anti-coxsackie B4, and anti-EV71 activities, with IC50
values of 4.48e93.58 mg/mL. Anti-coxsackie B3 activ-
ity with an IC50 value of 6.20 mg/mL was exhibited by Z.
coreanum. Furthermore, Z. piperitum, Z. schinifolium, Z.
planispinum, and Z. coreanum possessed strong antiviral
activity against EV71, with IC50 values ranging from
<0.1 mg/mL to 56.05 mg/mL (Tables 1 and 2).
Cytotoxicity of each extract was evaluated in par-
allel with antiviral activity evaluation. As a result, Z.
planispinum among the above extracts showing anti-
viral activity was slightly toxic to HeLa cells, with a
CC50 value of 224.70 mg/mL. Z. planispinum among
them was also slightly toxic to Vero cells, with a CC50
value of 345.35 mg/mL. Its therapeutic index is shown





Z. piperitum > 100 59.48 5.01
Z. schinifolium 202.30 47.05 18.02
Z. coreanum > 100 NDx
Z. planispinum 345.35 66.55 8.52
Ribavirin > 100 21.74 1.53
*The 50% cytotoxic concentration for Hela cells in mg/mL; yConcentration of c
effects; zTherapeutic indexZ CC50/IC50;
xIC50 value within the concentration of
under 50%. Results are presented as the mean IC50 values obtained from thre
rhinovirus; IC50Z 50% inhibition concentration; NDZ not determined; SDZ






Z. piperitum > 100 45.80 2.45 > 2.18 68.53 4.72
Z. schinifolium > 100 NDx d NDx
Z. coreanum > 100 NDx d 6.20 0.70
Z. planispinum 224.70 NDx d 39.87 8.73
Ribavirin 191.64 NDx d NDx
*The 50% cytotoxic concentration for Vero cells in mg/mL; yConcetration of c
effects; zTherapeutic indexZ CC50/IC50;
xIC50 value within the concentration of
under 50%. Results are presented as the mean IC50 values obtained from three
A16; CB3Z coxsackie B3; CB4Z coxsackie B4; EV71Z human enterovir
NDZ not determined; SDZ standard deviation; TIZ therapeutic index.4. Discussion
In this study, ribavirin showed weak antiviral activity
in HeLa cells infected with HRV2, but did not possess
antiviral activity against HRV3 and four enteroviruses.
Therefore, we were able to ascertain that ribavirin pos-
sesses some antiviral properties, although it is strongly
influenced by the strain of virus tested.
Previous studies of rhinovirus capsid-binding com-
pounds tested against serotype HRVs revealed the ex-
istence of another serotype HRVs, based on differential
susceptibility to antiviral compounds [11]. In 2002, the
U.S. Food and Drug Administration did not approve
pleconaril for the treatment of the common cold, as the
panel remained unconvinced about the drug’s safety
profile [12]. Medicinal plants are increasingly being
pursued as suitable alternative sources for discovery of
antiviral agents [13,14]. It has been reported that Z.
piperitum (leaves) possesses strong antiviral activity
against human influenza virus [15]. Z. schinifolium
(barks and stems) has been reported to exhibit anti-
hepatitis B virus activity [16]. However, until now, no
effective treatment has shown broad-spectrum antiviral
activity. In this study, Z. piperitum showed broad-




> 1.68 39.94 0.27 > 2.5
4.3 47.48 7.18 4.26
d NDx d
5.19 29.58 7.58 11.68
> 4.6 42.21 9.21 > 2.37
ompound in mg/mL producing 50% inhibition of virus-induced cytopathic
the compound to be tested not determined due to maximum inhibition rate
e independent experiments carried out in triplicate SD. HRVZ human






> 1.46 93.58 2.74 > 1.07 4.48 0.90 > 22.35
d 70.02 4.74 > 1.43 < 0.1 > 1,000
> 16.13 NDx d < 0.1 > 1,000
5.64 75.70 6.34 2.97 56.05 4.50 4.01
d NDx d NDx d
ompound in mg/mL producing 50% inhibiton of virus-induced cytopathic
the compound to be tested not determined due to maximum inhibition rate
independent experiments carried out in triplicate SD. CA16Z coxsackie
us 71; HRVZ human rhinovirus; IC50Z 50% inhibition concentration;
Antipicornavirus activity of Zanthoxylum species 403enteroviruses, with differences in inhibitory efficacy
among the strains. Therefore, further studies on the
isolation of antiviral compounds from Z. piperitum are
necessary.Conflicts of interest
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